Evommune (NYSE:EVMN) Insider Sells $33,480.00 in Stock

Evommune, Inc. (NYSE:EVMN) insider Jeegar Pravinkumar Patel sold 1,488 shares of Evommune stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $22.50, for a total transaction of $33,480.00. Following the completion of the sale, the insider directly owned 46,403 shares in the company, valued at approximately $1,044,067.50. The trade was a 3.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jeegar Pravinkumar Patel also recently made the following trade(s):

• On Monday, June 1st, Jeegar Pravinkumar Patel sold 16,687 shares of Evommune stock. The shares were sold at an average price of $22.74, for a total transaction of $379,462.38.

Evommune Trading Up 3.3%

Shares of EVMN opened at $24.93 on Friday. Evommune, Inc. has a twelve month low of $13.89 and a twelve month high of $33.20. The stock’s 50 day moving average is $22.98 and its two-hundred day moving average is $22.31. The firm has a market capitalization of $898.16 million and a PE ratio of -2.62.

Evommune (NYSE:EVMN) last issued its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. On average, sell-side analysts predict that Evommune, Inc. will post -2.85 EPS for the current year.

Hedge Funds Weigh In On Evommune

Several hedge funds have recently added to or reduced their stakes in EVMN. Strs Ohio acquired a new position in Evommune during the first quarter worth about $41,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Evommune in the fourth quarter valued at approximately $34,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Evommune in the fourth quarter valued at approximately $179,000. XTX Topco Ltd purchased a new position in shares of Evommune during the 4th quarter worth approximately $321,000. Finally, Oxford Asset Management LLP acquired a new position in shares of Evommune during the 4th quarter worth approximately $335,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on EVMN shares. Morgan Stanley boosted their target price on shares of Evommune from $54.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $48.00 price objective on shares of Evommune in a research note on Friday, April 10th. Oppenheimer started coverage on shares of Evommune in a report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 price objective on the stock. Stifel Nicolaus initiated coverage on shares of Evommune in a research report on Friday, May 1st. They set a “buy” rating and a $54.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Evommune in a report on Tuesday, May 26th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $49.25.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.